Morgan Stanley Taysha Gene Therapies, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Morgan Stanley holds 16,865,082 shares of TSHA stock, worth $77.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,865,082

Previous 16,846,374 0.11%

Holding current value

$77.4 Million

Previous $23.4 Million 66.37%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$1.13 - $2.9 $21,140 - $54,253	18,708 Added 0.11%	16,865,082 $39 Million
Q1 2025 May 15, 2025	SELL	$1.39 - $2.05 $1.1 Million - $1.63 Million	-793,992 Reduced 4.5%	16,846,374 $23.4 Million
Q4 2024 Feb 14, 2025	BUY	$1.27 - $3.24 $12.7 Million - $32.3 Million	9,976,373 Added 130.17%	17,640,366 $30.5 Million
Q3 2024 May 14, 2025	BUY	$2.01 - $2.46 $375,057 - $459,026	186,596 Added 2.5%	7,663,993 $15.4 Million
Q3 2024 Nov 14, 2024	BUY	$2.01 - $2.46 $375,057 - $459,026	186,596 Added 2.5%	7,663,993 $15.4 Million
Q2 2024 May 14, 2025	SELL	$2.04 - $4.17 $20.7 Million - $42.4 Million	-10,162,969 Reduced 57.61%	7,477,397 $16.7 Million
Q2 2024 Oct 17, 2024	BUY	$2.04 - $4.17 $4.71 Million - $9.63 Million	2,308,507 Added 44.66%	7,477,397 $16.7 Million
Q2 2024 Aug 14, 2024	BUY	$2.04 - $4.17 $4.71 Million - $9.63 Million	2,308,507 Added 44.66%	7,477,397 $16.7 Million
Q1 2024 Oct 17, 2024	SELL	$1.43 - $3.25 $3.3 Million - $7.5 Million	-2,308,507 Reduced 30.87%	5,168,890 $14.8 Million
Q1 2024 Aug 16, 2024	BUY	$1.43 - $3.25 $7.08 Million - $16.1 Million	4,952,352 Added 2287.06%	5,168,890 $14.8 Million
Q1 2024 May 15, 2024	BUY	$1.43 - $3.25 $7.08 Million - $16.1 Million	4,952,352 Added 2287.06%	5,168,890 $14.8 Million
Q4 2023 Aug 16, 2024	SELL	$1.33 - $2.88 $9.66 Million - $20.9 Million	-7,260,859 Reduced 97.1%	216,538 $383,000
Q4 2023 Feb 13, 2024	BUY	$1.33 - $2.88 $59,143 - $128,070	44,469 Added 25.84%	216,538 $383,000
Q3 2023 Nov 15, 2023	BUY	$0.63 - $3.66 $25,679 - $149,185	40,761 Added 31.04%	172,069 $543,000
Q2 2023 Aug 14, 2023	BUY	$0.59 - $0.87 $25,662 - $37,840	43,495 Added 49.53%	131,308 $86,000
Q1 2023 May 15, 2023	BUY	$0.65 - $2.3 $41,733 - $147,673	64,206 Added 271.98%	87,813 $70,000
Q4 2022 Feb 14, 2023	SELL	$1.39 - $2.98 $1,883 - $4,037	-1,355 Reduced 5.43%	23,607 $53,000
Q3 2022 Nov 14, 2022	SELL	$1.76 - $4.94 $82,172 - $230,643	-46,689 Reduced 65.16%	24,962 $48,000
Q2 2022 Oct 27, 2022	SELL	$2.47 - $6.77 $257,136 - $704,784	-104,104 Reduced 59.23%	71,651 $265,000
Q2 2022 Aug 15, 2022	SELL	$2.47 - $6.77 $257,136 - $704,784	-104,104 Reduced 59.23%	71,651 $265,000
Q1 2022 Oct 27, 2022	BUY	$5.22 - $11.86 $543,422 - $1.23 Million	104,104 Added 145.29%	175,755 $1.15 Million
Q1 2022 May 13, 2022	BUY	$5.22 - $11.86 $174,400 - $396,242	33,410 Added 23.47%	175,755 $1.15 Million
Q4 2021 Feb 14, 2022	BUY	$11.43 - $19.2 $197,178 - $331,219	17,251 Added 13.79%	142,345 $1.66 Million
Q3 2021 Nov 15, 2021	BUY	$15.82 - $21.57 $1.98 Million - $2.7 Million	125,094 New	125,094 $2.33 Million

Others Institutions Holding TSHA

# of Institutions

154

Shares Held

244M

Call Options Held

107K

Put Options Held

17K

View Full List

About Taysha Gene Therapies, Inc.

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $222M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

More about TSHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account